Meeting
2022 ASCO Annual Meeting
Immune tumor microenvironnement (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: Novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO/GINEGEPS study.
Authors
Felix Blanc-Durand
Institut Gustave Roussy, Villejuif, France
Felix Blanc-Durand , Elisa Yaniz-Galende , Catherine Genestie , Hortense Gauthier De Saint Basile , Laure Chardin , Gaetan De Rauglaudre , Nadia Raban , Annick Chevalier , Gwenael Ferron , Marie-Christine Kaminsky , Isabelle Laure Ray-Coquard , Salima Hamizi , Pierre Combe , Sophie Abadie Lacourtoisie , Florence Joly , Jérome Meunier , Anne Floquet , Jérôme Alexandre , Audrey Le Formal , Alexandra Leary
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5554)
DOI
10.1200/JCO.2022.40.16_suppl.5554
Abstract #
5554
Poster Bd #
433
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer.
First Author: Stephanie Gaillard
Poster
2016 ASCO Annual Meeting
Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).
First Author: Nicole Grace Chau
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2023 ASCO Annual Meeting
Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC).
First Author: Francesca Battaglin